Lembaz FDA Approval: First Drug to Extend Survival in Infantile Niemann-Pick Type C
The FDA approved Beren Therapeutics' Lembaz (adrabetadex), the first drug shown to extend survival in infantile-onset Niemann-Pick disease type C. The survival data, hearing risks and what comes next.
